Literature DB >> 6090602

Intratumoral autologous mononuclear cells in the treatment of recurrent glioblastoma multiforme. A phase 1 (toxicity) study.

P Steinbok, J P Thomas, L Grossman, C L Dolman.   

Abstract

Four patients with malignant gliomas recurring after surgical resection, radiotherapy and chemotherapy were entered into a trial of immunotherapy. Partial removal of the recurrent tumors was performed and autologous mononuclear cell infusions were given into the resection cavity via a subgaleal reservoir that had been inserted at the time of tumor resection. Mononuclear cells were obtained using a cell separator and Ficoll-hypaque separation techniques. Patients were followed carefully with clinical examinations, CT brain scans and immunological testing. All patients have died and complete autopsies were done. We looked specifically for evidence of mononuclear cell penetration into the tumor and possible adverse effects on the normal brain or in the rest of the body. The results indicate that this type of therapy can be performed safely and may be useful in the treatment of patients with malignant gliomas.

Entities:  

Mesh:

Year:  1984        PMID: 6090602     DOI: 10.1007/bf00177901

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  23 in total

1.  IS THE BRAIN "AN IMMUNOLOGICALLY PRIVILEGED SITE"?I. STUDIES BASED ON INTRACEREBRAL TUMOR HOMOTRANSPLANTATION AND ISOTRANSPLANTATION TO SENSITIZED HOSTS.

Authors:  L C SCHEINBERG; F L EDELMAN; W A LEVY
Journal:  Arch Neurol       Date:  1964-09

2.  Cell-bound antiglial immunity in patients with malignant tumors of the brain.

Authors:  T Wahlström; E Saksela; H Troupp
Journal:  Cell Immunol       Date:  1973-02       Impact factor: 4.868

3.  In vitro demonstration of cell-mediated immunity to human brain tumors.

Authors:  N L Levy; M S Mahaley; E D Day
Journal:  Cancer Res       Date:  1972-03       Impact factor: 12.701

4.  Tumour-associated surface antigen(s) in human astrocytomas.

Authors:  H B Coakham; M S Lakshmi
Journal:  Oncology       Date:  1975       Impact factor: 2.935

5.  Immunobiology of primary intracranial tumors. Part 1: studies of the cellular and humoral general immune competence of brain-tumor patients.

Authors:  M S Mahaley; W H Brooks; T L Roszman; D D Bigner; L Dudka; S Richardson
Journal:  J Neurosurg       Date:  1977-04       Impact factor: 5.115

6.  Lymphocytic infiltrates in primary glioblastomas and recidivous gliomas. Incidence, fate, and relevance to prognosis in 228 operated cases.

Authors:  L Palma; N Di Lorenzo; B Guidetti
Journal:  J Neurosurg       Date:  1978-12       Impact factor: 5.115

7.  Immunobiology of primary intracranial tumours. II. Analysis of lymphocyte subpopulations in patients with primary brain tumours.

Authors:  W H Brooks; T L Roszman; M S Mahaley; R E Woosley
Journal:  Clin Exp Immunol       Date:  1977-07       Impact factor: 4.330

8.  Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery.

Authors:  M D Walker; S B Green; D P Byar; E Alexander; U Batzdorf; W H Brooks; W E Hunt; C S MacCarty; M S Mahaley; J Mealey; G Owens; J Ransohoff; J T Robertson; W R Shapiro; K R Smith; C B Wilson; T A Strike
Journal:  N Engl J Med       Date:  1980-12-04       Impact factor: 91.245

9.  Immunobiology of primary intracranial tumours. III. Demonstration of a qualitative lymphocyte abnormality in patients with primary brain tumours.

Authors:  T L Roszman; W H Brooks
Journal:  Clin Exp Immunol       Date:  1980-02       Impact factor: 4.330

10.  [Frequency and significance of lymphoplasmocyte infiltration in human gliomas (author's transl)].

Authors:  D Schiffer; G Croveri; C Pautasso
Journal:  Tumori       Date:  1974 May-Jun
View more
  11 in total

Review 1.  Immunotherapy for primary brain tumors: no longer a matter of privilege.

Authors:  Peter E Fecci; Amy B Heimberger; John H Sampson
Journal:  Clin Cancer Res       Date:  2014-11-15       Impact factor: 12.531

2.  Adoptive immunotherapy using lymphokine-activated killer (LAK) cells and interleukin-2 for recurrent malignant primary brain tumors.

Authors:  S K Sankhla; J S Nadkarni; S N Bhagwati
Journal:  J Neurooncol       Date:  1996-02       Impact factor: 4.130

Review 3.  Neuro-oncology index and review (adult primary brain tumors). Radiotherapy, chemotherapy, immunotherapy, photodynamic therapy.

Authors:  M S Mahaley
Journal:  J Neurooncol       Date:  1991-10       Impact factor: 4.130

Review 4.  Toward effective immunotherapy for the treatment of malignant brain tumors.

Authors:  Duane A Mitchell; John H Sampson
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

Review 5.  Experimental approaches for the treatment of malignant gliomas.

Authors:  Leopold Arko; Igor Katsyv; Grace E Park; William Patrick Luan; John K Park
Journal:  Pharmacol Ther       Date:  2010-06-08       Impact factor: 12.310

Review 6.  Genetics and immunotherapy: using the genetic landscape of gliomas to inform management strategies.

Authors:  Joanna Y Wang; Chetan Bettegowda
Journal:  J Neurooncol       Date:  2015-02-21       Impact factor: 4.130

7.  Cellular immunotherapy for high-grade glioma.

Authors:  K H Chow; Stephen Gottschalk
Journal:  Immunotherapy       Date:  2011-03       Impact factor: 4.196

Review 8.  Immunotherapy of malignant brain tumors.

Authors:  Duane A Mitchell; Peter E Fecci; John H Sampson
Journal:  Immunol Rev       Date:  2008-04       Impact factor: 12.988

Review 9.  Biological intratumoral therapy for the high-grade glioma part I: intratumoral delivery and immunotoxins.

Authors:  Joshua Loya; Charlie Zhang; Emily Cox; Achal S Achrol; Santosh Kesari
Journal:  CNS Oncol       Date:  2019-11-21

Review 10.  Chimeric antigen receptor T-cell therapy in glioblastoma: charging the T cells to fight.

Authors:  Craig A Land; Phillip R Musich; Dalia Haydar; Giedre Krenciute; Qian Xie
Journal:  J Transl Med       Date:  2020-11-11       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.